Pegylated interferon alfa 2b (PEG-IFN) and ribavirin for hepatitis C patients who were nonresponders to previous therapy

被引：0
|
作者：
Lawitz, EJ
Cantu, NS
Becker, S
Dhar, R
Li, J
Bala, NS
Gordon, S
Davis, M
Nader, P
Holtzmuller, K
Rosenfield, T
Monsour, H
机构：
来源：
GASTROENTEROLOGY | 2002年 / 122卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
80
引用
收藏
页码：A626 / A626
页数：1
相关论文
共 50 条
  • [21] Clinical characteristics of null responders to Peg-IFN alpha 2b/ribavirin therapy for chronic hepatitis C
    Suzuki, Hideyuki
    Kakizaki, Satoru
    Horiguchi, Norio
    Ichikawa, Takeshi
    Sato, Ken
    Takagi, Hitoshi
    Mori, Masatomo
    WORLD JOURNAL OF HEPATOLOGY, 2010, 2 (11) : 401 - 405
  • [22] Combination Therapy with Interferon-α2b, Ribavirin, and Amantadine in Chronic Hepatitis C Nonresponders to Interferon and Ribavirin
    Paul J. Thuluvath
    Hemant Pande
    Joyce Maygers
    Digestive Diseases and Sciences, 2003, 48 : 594 - 597
  • [23] Combination therapy with interferon-α2b, ribavirin, and amantadine in chronic hepatitis C nonresponders to interferon and ribavirin
    Thuluvath, PJ
    Pande, H
    Maygers, J
    DIGESTIVE DISEASES AND SCIENCES, 2003, 48 (03) : 594 - 597
  • [24] Pegylated interferon alpha 2b (PEG IFN) plus ribavirin (R) for treatment of chronic hepatitis C: Optimization of ribavirin dose
    Manns, M
    Mc Hutchison, JG
    Gordorn, S
    Rustgi, V
    Lee, MV
    Ling, ML
    Cohard, M
    Albrecht, JK
    JOURNAL OF HEPATOLOGY, 2001, 34 : 236 - 236
  • [25] Efficacy and safety of peg-IFN alfa-2a with ribavirin for the treatment of HCV/HIV coinfected patients who failed previous IFN based therapy
    Rodriguez-Torres, Maribel
    Rodriguez-Orengo, Jose F.
    Rios-Bedoya, Carlos F.
    Fernandez-Carbia, Alberto
    Gonzalez-Lassalle, Elsa
    Salgado-Mercado, Rosa
    Marxuach-Cuetara, Acisclo M.
    JOURNAL OF CLINICAL VIROLOGY, 2007, 38 (01) : 32 - 38
  • [26] Alfa interferon 2b and Ribavirin for treatment of patients with chronic hepatitis C who have failed alpha interferon 2b as single therapy.
    Blanchard, D
    Reed, T
    Freeman, S
    Weiner, K
    Bader, T
    HEPATOLOGY, 1998, 28 (04) : 284A - 284A
  • [27] Darbepoetin alfa (DA) for ribavirin-induced anemia in patients with chronic hepatitis C (CH-C) treated with pegylated interferon and ribavirin (peg-ifn/rbv): A preliminary analysis
    Younossi, ZM
    Ong, JP
    Collantes, R
    Assmann, JS
    Sjogren, R
    Sjogren, M
    Farmer, D
    Gujral, H
    Martin, L
    GASTROENTEROLOGY, 2004, 126 (04) : A666 - A666
  • [28] Interferon alfa 2b and ribavirin combination therapy for patients with chronic viral hepatitis C failing interferon therapy
    Galica, M
    Alhajjar, B
    Salen, G
    Dyrszka, H
    Sanghavi, B
    Eskreis, D
    HEPATOLOGY, 1998, 28 (04) : 709A - 709A
  • [29] Peginterferon alfa-2b and Ribavirin: Effective in Patients With Hepatitis C Who Failed Interferon alfa/Ribavirin Therapy
    Poynard, Thierry
    Colombo, Massimo
    Bruix, Jordi
    Schiff, Eugene
    Terg, Ruben
    Flamm, Steven
    Moreno-Otero, Ricardo
    Carrilho, Flair
    Schmidt, Warren
    Berg, Thomas
    McGarrity, Thomas
    Heathcote, E. Jenny
    Goncales, Fernando
    Diago, Moises
    Craxi, Antonio
    Silva, Marcelo
    Bedossa, Pierre
    Mukhopadhyay, Pabak
    Griffel, Louis
    Burroughs, Margaret
    Brass, Clifford
    Albrecht, Janice
    GASTROENTEROLOGY, 2009, 136 (05) : 1618 - 1628
  • [30] Pegylated interferon alfa-2b (PEG-IFN) plus ribavirin versus PEG-IFN for treatment of HIV/HCV co-infected patients (pts): An open, multicenter, randomized trial
    Cargnel, A
    Casella, A
    Angeli, E
    Gubertini, G
    Orlando, G
    Duca, P
    GASTROENTEROLOGY, 2002, 122 (04) : A630 - A630
12345